ADAMTSL4 in Idiopathic Pulmonary Hypertension and CTEPH

Sponsor

Wei Huang (Other)

Overall Status

Completed

CT.gov ID

NCT05478226

Collaborator

(none)

Enrollment

Location

Actual Duration (Months)

1.4

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

ADAMTSL4 (A disintegrin and metalloproteinase with thrombospondin motifs like) is a member of the ADAMTSL family. ADAMTSL4 is one of the family of 7 ADAMTS-Like proteins, themselves part of the Thrombospondin type 1 repeat (TSR) superfamily of proteins. These 7 proteins are divided into two distinct clades, of which ADAMTSL4 and ADAMTS-Like 6 form part of one clade, differing from ADAMTS-Like 1, ADAMTS-Like 3 and ADAMTS-Like 7 by lacking immunoglobulin repeat regions. ADAMTSL4 is widely expressed in brain, colon, heart, kidney, liver, lung, pancreas and spleen, yet, its precise role is unclear. in addition, ADAMTSL4 protein high expression to the medial layer of the arterial wall, and medial vascular smooth muscle cells specifically.

Condition or Disease	Intervention/Treatment	Phase
Pulmonary Hypertension	Other: drugs or BPA

Detailed Description

The objectives of the present study aimed to confirm ADAMTSL4 levels in the proteomics between healthy control population and patients with IPAH，to analyze the expression levels of ADAMTSL4 between patients with IPAH and CTEPH, and to investigate whether serum levels of ADAMTSL4 might be used as biomarkers of disease severity in these patient populations.

Study Design

Study Type:

Observational

Actual Enrollment :

67 participants

Observational Model:

Cohort

Time Perspective:

Retrospective

Official Title:

ADAMTSL4 in Idiopathic Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

Actual Study Start Date :

Jul 1, 2018

Actual Primary Completion Date :

Aug 31, 2020

Actual Study Completion Date :

Jul 1, 2022

Arms and Interventions

Arm	Intervention/Treatment
control group healthy people as control group
IPAH group patients with IPAH as IPAH group	Other: drugs or BPA PAH target drugs，for example， Tadanafiland, Maxitensin, Prostacyclins, riociguat and etc. CTEPH treat with balloon pulmonary angioplasty or riociguat
CTEPH group patients with CTEPH as CTEPH group	Other: drugs or BPA PAH target drugs，for example， Tadanafiland, Maxitensin, Prostacyclins, riociguat and etc. CTEPH treat with balloon pulmonary angioplasty or riociguat
group D Including CTEPH group and IPAH group	Other: drugs or BPA PAH target drugs，for example， Tadanafiland, Maxitensin, Prostacyclins, riociguat and etc. CTEPH treat with balloon pulmonary angioplasty or riociguat

Outcome Measures

Primary Outcome Measures

Association of clinic index and ADAMTSL4 expression level [2018-2022]
The expression and its clinical relevance of ADAMTSL4 expression level in plasma or pulmonary tissue in patients with IPAH and CTEPH

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 80 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Yes

Inclusion Criteria:

Healthy people，patients with IPAH，patients with CTEPH

Exclusion Criteria:

tumour，infection，Pregnancy, suckling period， Mental disorders，

Other types of PAH except CTEPH and IPAH

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	the First Affiliated Hospital, Chongqing Medical University	Chongqing	Chongqing	China	400016

Sponsors and Collaborators

Wei Huang

Investigators

Principal Investigator: Wei Huang, Phd, First Affiliated Hospital of Chongqing Medical University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

Wei Huang, Professor, First Affiliated Hospital of Chongqing Medical University

ClinicalTrials.gov Identifier:

NCT05478226

Other Study ID Numbers:

2019XMSB000726

First Posted:

Jul 28, 2022

Last Update Posted:

Jul 28, 2022

Last Verified:

Jul 1, 2022

Individual Participant Data (IPD) Sharing Statement:

Undecided

Plan to Share IPD:

Undecided

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Additional relevant MeSH terms:

Hypertension, Pulmonary

Hypertension

Study Results

No Results Posted as of Jul 28, 2022